CANNABICS™
RCC-33

The world’s first cannabinoid-based antitumor Drug Candidate for the treatment of Colorectal Cancer based on our novel and proprietary formulation Cannabics™ RCC-33

CANNABICS PHARMACEUTICALS

Proud to be a global leader in the development
of cancer related cannabinoid-based therapeutic
formulations and medicines
 Yellow marker: dead cancer cells after 24 hrs.

PIONEER IN CANNABINOID-BASED ANTITUMOR RESEARCH

Cannabics Pharmaceuticals has been
conducting research on the antitumor effects of
cannabinoid formulations on cancer since its
establishment in 2012.

Drug
Discovery

Cannabics Pharmaceuticals’ groundbreaking research and development is carried in its in-house state of the art drug discovery facility.